[F]-FDopa positron emission tomography imaging in corticobasal syndrome.

Purpose: First, to investigate the patterns of [F]-FDOPA positron emission tomography imaging in corticobasal syndrome using visual and semi-quantitative analysis and to compare them with patterns found in Parkinson's disease and progressive supranuclear palsy. Then, to search for correlations with clinical features and [F]-FDG positron emission tomography imaging.

Methods: 27 corticobasal syndrome patients who underwent [F]-FDOPA positron emission tomography imaging were retrospectively studied.

A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer.

Purpose: To evaluate the efficacy and safety of dabrafenib-trametinib-131I for the treatment of radioactive iodine refractory metastatic differentiated thyroid cancer (DTC) with a BRAF p.V600E mutation.

Patients And Methods: A prospective phase II trial including patients with RECIST progression within 18 months and no lesion > 3 cm.

Prognostic value of immunotherapy-induced organ inflammation assessed on FDG PET in patients with metastatic non-small cell lung cancer.

Purpose: We evaluated the prognostic value of immunotherapy-induced organ inflammation observed on FDG PET in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICPIs).

Methods: Data from patients with IIIB/IV NSCLC included in two different prospective trials were analyzed. FDG PET/CT exams were performed at baseline (PET) and repeated after 7-8 weeks (PET1) and 12-16 weeks (PET2) of treatment, using iPERCIST for tumor response evaluation.